UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings. Crown Medical Collections (“Crown Medical”), which serves as special counsel to the Debtors for the collection of a ...

Core Insights - ProPhase Labs, Inc. has successfully uplisted its common stock from the Pink Sheets to the OTC market, marking a significant milestone for the company [1][2] - The company is experiencing positive momentum in its Crown Medical collections initiative and plans to provide an operational update soon, along with a strategic update on its BE-Smart® Esophageal Cancer Test [2] - ProPhase Labs is focused on enhancing its financial position and advancing initiatives aimed at long-term shareholder value [2] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company dedicated to building a healthier world through innovation and actionable insights [3] - The company is involved in Whole Genome Sequencing solutions, diagnostic development, and a direct-to-consumer marketing platform for OTC dietary supplements [3] - ProPhase Labs aims to develop, manufacture, and commercialize health and wellness solutions, emphasizing executional excellence and smart diversification [3]

Core Viewpoint - ProPhase Labs, Inc. is addressing recent stock price volatility attributed to technical factors, including convertible debt conversion and a reverse stock split, while emphasizing the stability of its underlying asset value [2][3][5]. Group 1: Stock Price Volatility - The company believes that recent stock price fluctuations are due to short-term technical factors, such as the conversion and resale of convertible debt and the transition from Nasdaq to the OTC market [2]. - Over $3.3 million of the $3.8 million convertible debt has been converted, leading to a reduction in company debt and an increase in shareholders' equity [3]. - The remaining unconverted balance of convertible debt is less than $500,000, and recent conversions occurred at a price of approximately $0.76 per share, which is above the current trading price [4]. Group 2: Financial Health and Asset Value - The conversion of debt has increased the number of outstanding shares but has also reduced liabilities, thereby strengthening the company's balance sheet [5]. - The intrinsic value of ProPhase Labs' assets remains unchanged despite the capital structure changes, with significant underlying value in its operating subsidiaries and assets [5]. - The company is focused on stabilizing its capital structure and advancing core business operations, indicating that recent trading volatility does not reflect changes in long-term strategy or growth prospects [5]. Group 3: Company Overview - ProPhase Labs is a biotech and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests [7]. - The company aims to revolutionize healthcare and is committed to executional excellence and smart diversification [7].

Prophase Labs (NasdaqCM:PRPH) Conference Call Summary Company Overview - **Company**: Prophase Labs - **Ticker**: PRPH - **Industry**: Biotechnology and Diagnostics Key Points Company Structure and Financials - Prophase Labs has several divisions: - **Crown Medical**: Expected to net $50 million after contingency fees and discounted settlements with insurance companies [3][4] - **Prophase Biopharma**: Focused on the BE-Smart esophageal cancer test, which has multi-billion-dollar potential [4] - **Nebula Genomics**: Recently restructured to become a break-even to profitable business [4] - **Supplements Business**: Development contingent on available capital [5] Merger and LOI with ABL - A non-binding Letter of Intent (LOI) has been signed with ABL, a European biotech company, to pursue a merger that could create significant synergies [5][6] - The merger could value Prophase Labs at up to $30 million, with a proposed structure of 76% ownership for ABL and 24% for Prophase Labs [7] - Up to $10 million will be set aside for current Prophase Labs shareholders from the funds raised by investment bankers [7][8] Crown Medical Initiative - Prophase Labs is pursuing collections from approximately 1,000 insurance companies through a bankruptcy strategy, which is expected to expedite litigation [12][13] - Crown Medical is optimistic about collecting at least $50 million, with initial cash flow expected in the coming months [17][18] BE-Smart Esophageal Cancer Test - The BE-Smart test aims to improve the accuracy of esophageal cancer diagnosis, which is currently low due to the limitations of endoscopy [19][20] - The potential market for the test is estimated at $7-$14 billion, with significant implications for healthcare cost savings [24] Nebula Genomics - Nebula Genomics focuses on whole genome sequencing, providing in-depth health-related information, and has a large database equivalent to over 150 million ancestry tests [25][26] - The business model has shifted to annual subscriptions, which may enhance profitability [26] NASDAQ Compliance and Reverse Split - A 1-for-10 reverse stock split is scheduled, aimed at maintaining NASDAQ compliance [27][28] - The company believes it will successfully appeal any potential delisting due to stock price issues [36][38] Future Outlook - Prophase Labs is optimistic about multiple paths to success, including the merger, Crown Medical collections, and the commercialization of the BE-Smart test [29][63] - The management team is focused on realizing the underlying value of the company, with expectations for a positive 2026 [65][66] Additional Considerations - The merger with ABL is seen as a win-win, providing both companies with valuable assets and market presence [32][41] - Current shareholders will benefit from the carve-out of Crown Medical collections and the special dividend [54][55] Conclusion Prophase Labs is positioned for significant growth through its strategic initiatives, including the merger with ABL, the Crown Medical collections, and the commercialization of its diagnostic tests. The company is optimistic about its future and is actively working to enhance shareholder value.

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining over 200 points, up 0.49% to 48,188.36, NASDAQ rising 1.03% to 23,243.38, and S&P 500 increasing 0.73% to 6,824.15 [1] - Information technology shares rose by 1.6%, while real estate stocks fell by 0.1% [1] Company Performance - Conagra Brands Inc (NYSE:CAG) shares fell more than 4% after reporting second-quarter earnings of 45 cents per share, beating the analyst consensus estimate of 44 cents, but quarterly sales of $2.979 billion missed the estimate of $2.986 billion [2] Commodity Market - Oil traded up 1% to $56.47, while gold decreased by 0.2% to $4,365.60. Silver fell 1.9% to $65.640, and copper rose 0.1% to $5.4360 [4] Global Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.1%, Spain's IBEX 35 up 0.2%, London's FTSE 100 up 0.2%, Germany's DAX 40 rising 0.2%, and France's CAC 40 gaining 0.1% [5] - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.03%, Hong Kong's Hang Seng up 0.75%, China's Shanghai Composite rising 0.36%, and India's BSE Sensex increasing 0.53% [6] Notable Stock Movements - Autozi Internet Technology (NASDAQ:AZI) shares surged 85% to $2.81 after a $90 million initial equity investment was confirmed by a strategic investor [8] - Julong Holding Ltd (NASDAQ:JLHL) shares increased by 43% to $4.37, while ProPhase Labs Inc (NASDAQ:PRPH) shares rose 44% to $0.15 following a non-binding LOI for a proposed reverse merger [8] - Geovax Labs Inc (NASDAQ:GOVX) shares dropped 47% to $0.13, and Nisun International Enterprise Development Group Co Ltd (NASDAQ:NISN) fell 44% to $1.86 [8]

Business Verticals & Strategic Initiatives - ProPhase Labs is pursuing near-term cash recovery of over $50 million from COVID-19 receivables through Crown Medical Collections [7, 11, 24, 26, 92] - BE-Smart, an esophageal cancer diagnostic test, targets a $7-14 billion market [8, 34] - Nebula Genomics possesses a 16-petabyte DNA dataset, equivalent to roughly 150 million ancestry SNP-based tests, spanning 130 countries [9, 62] - ProPhase Labs signed a Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S A (ABL), with ABL potentially becoming the majority owner (~76%) [20, 23] BE-Smart Esophageal Cancer Diagnostic - BE-Smart achieved greater than a 95% technical success rate in a key validation study evaluating its performance with esophageal brush cytology samples [44, 93] - The change in the annual incidence of Esophageal Adenocarcinoma (EAC) was 766 67% higher in 2017 compared to 1973 [32] Nebula Genomics - Nebula Genomics' DNA Complete offers Whole Genome Sequencing (WGS) analyzing virtually 100% of an individual's DNA [63] - DNA Expand expands raw DNA data more than 50 times to over 35 million genetic variants [73] Financial Restructuring - ProPhase Labs sold Pharmaloz Manufacturing for $23 6 million [18] - The company is saving over $6 million per year by shutting down the genomics laboratory [18]

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call today at 10:00 a.m. ET UNIONDALE, NY, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase") and Advanced Biological Laboratories S.A. ("ABL"), a European biotechnology and MedTech group, today announced that they have entered into a non-binding Letter of Intent ("LOI") regarding a propos ...

Core Viewpoint - ProPhase Labs is hosting a webinar to discuss its business and future prospects, featuring CEO Ted Karkus [3]. Group 1: Company Overview - ProPhase Labs trades on NASDAQ under the ticker PRPH [3]. - The webinar is organized in collaboration with RedChip Companies [3]. Group 2: Presentation Details - The event will include a brief presentation followed by a Q&A session [3]. - The operator mentions the inclusion of forward-looking statements as per the Private Securities Litigation Reform Act of 1995 [3].

Core Viewpoint - Samsung Electronics has launched its first multi-folding smartphone to enhance its competitive position in a rapidly intensifying segment of the smartphone market [1] Group 1 - The introduction of the multi-folding smartphone signifies Samsung's commitment to innovation in the mobile device sector [1] - The move is expected to strengthen Samsung's market presence as competition in the smartphone industry escalates [1]

Core Insights - ProPhase Labs, Inc. is hosting a webinar on December 1, 2025, featuring insights from Chairman and CEO Ted Karkus [1][2] - The company will discuss its healthcare assets, including the BE-Smart™ Esophageal Cancer Test, which targets a market valued between $7 billion and $14 billion [2] - ProPhase is also focusing on recovering over $50 million in COVID-19 receivables and expanding its consumer genomics business, Nebula Genomics [2] Company Overview - ProPhase Labs is a next-generation biotech and consumer products company dedicated to healthcare innovation and actionable insights [5] - The company is involved in Whole Genome Sequencing and developing diagnostics for early cancer detection [5] - ProPhase aims to create long-term value through executional excellence and a synergistic approach across its subsidiaries [5]